Teva Pharmaceutical Industries Ltd. (TEVA) said it currently expects fiscal 2012 non-GAAP earnings per share between $5.30 and $5.40, whereas 28 analysts estimate earnings per share of $5.59 for the year.
For the full year 2012, the company sees total net sales of around $20 billion - $21 billion, consisting of total U.S. net sales of $10.5 billion, total European net sales of $5.8 billion, and total ROW net sales of $4.2 billion. Analysts project sales of $21.27 billion for 2012.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.